Albrecht Stenzinger is Professor of Molecular Tumor Pathology and the Head of the IPH Center for Molecular Pathology (CMP) as well as Section Head for Molecular Diagnostics and Biomarker Development at the Institute of Pathology (IPH), University Hospital Heidelberg, Germany. He is holding an MD degree from the University of Giessen (Germany), completed his residency and fellowship training in pathology at the Charité University Hospital in Berlin and the University Hospital Heidelberg (Germany) and is a board-certified surgical pathologist and senior attending. Albrecht received postdoctoral training at the University of Heidelberg, Germany and Massachusetts General Hospital/Harvard Medical School, USA. He has a broad expertise in molecular pathology and works in the field of translational research and genetics of lung cancer.
- Molecular prediction of immune checkpoint blockade
- Resistance to targeted therapy and ICB
Lung cancer
- Kazdal D, Endris V, Allgäuer M, Kriegsmann M, Leichsenring J, Volckmar AL, Harms A, Kirchner M, Kriegsmann K, Neumann O, Brandt R, Talla SB, Rempel E, Ploeger C, von Winterfeld M, Christopoulos P, Merino DM, Stewart M, Allen J, Bischoff H, Meister M, Muley T, Herth F, Penzel R, Warth A, Winter H, Fröhling S, Peters S, Swanton C, Thomas M, Schirmacher P, Budczies J, Stenzinger A. Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts. J Thorac Oncol. 2019
- Budczies J, Allgäuer M, Litchfield K, Rempel E, Christopoulos P, Kazdal D, Endris V, Thomas M, Fröhling S, Peters S, Swanton C, Schirmacher P, Stenzinger A. Optimizing panel-based tumor mutational burden (TMB) measurement. Ann Oncol. 2019 Sep 1;30(9):1496-1506.
- Volckmar AL, Leichsenring J, Kirchner M, Christopoulos P, Neumann O, Budczies J, Morais de Oliveira CM, Rempel E, Buchhalter I, Brandt R, Allgäuer M, Talla SB, von Winterfeld M, Herpel E, Goeppert B, Lier A, Winter H, Brummer T, Fröhling S, Faehling M, Fischer JR, Heußel CP, Herth F, Lasitschka F, Schirmacher P, Thomas M, Endris V, Penzel R, Stenzinger A. Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000
Heidelberg cases. Int J Cancer. 2019 Jan 17. - Ertych N*, Stolz A*, Stenzinger A, Weichert W, Kaulfuß S, Burfeind P, Aigner A, Wordeman L, Bastians H. Increased microtubule assembly rates influence chromosomal instability in colorectal cancer cells. Nat Cell Biol. 2014 Aug;16(8):779-91.
- Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, Klein C, Saini M, Bäuerle T, Wallwiener M, Holland-Letz T, Höfner T, Sprick M, Scharpff M, Marmé F, Sinn HP, Pantel K, Weichert W, Trumpp A. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol. 2013 Jun;31(6):539-44.
Daniel Kazdal | |||||
Martina Kirchner | |||||
Anna-Lena-Volckmar | |||||
Michael Allgäuer | |||||
Julia Glade |
Lung Research – Projects
With his background as a surgical and molecular pathologist, he has an interdisciplinary view on research and across diseases. The main focus of his group is on thoracic malignancies (i.e. primarily lung cancer and mesothelioma) including premalignant lesions and conditions that can ultimately result in malignant disease. His research group as well as the Center for Molecular Pathology (CMP, at the Institute of Pathology) which he is leading, have a dedicated and ample experience in the molecular analysis of non-small cell lung cancer. The main expertise is translational research with translation towards true clinical applications as well as reverse translation by which clinico-molecular datasets can inform and support basic research teams. To this end, they have developed an arsenal of tools that enables them to obtain molecular information on the DNA- and RNA-level from tiny biopsies and even formalin-fixed and paraffin-embedded material.
Current main projects focus on i) molecular prediction of immune checkpoint blockade (ICB) response and ii) mechanisms of resistance to targeted therapy and ICB.